The Purpose of This Study is to Evaluate the Safety and Efficacy of D-MNA in Adult Patients With Nodular Basal Cell Carcinoma

Eligibility Criteria

• 1. Male or non-pregnant female ≥ 18 years of age.
• 2. Clinical diagnosis of a primary, previously untreated, histologically confirmed nodular Basal Cell Carcinoma (nBCC) lesion suitable for excision (at end of the study) with a minimum diameter of 0.5 cm and with a maximum longest diameter of 1.3 cm at the time of biopsy and Visit 2/Baseline.
• 3. Willing to refrain from exposure to excessive direct sunlight or ultraviolet light and to avoid the use of tanning beds for the duration of the study.
• 4. Willing and able to receive the test article treatments, comply with study instructions, and commit to all follow-up visits for the duration of the study.
• 1. Pregnant, lactating, or planning to become pregnant.
• 2. nBCC is located on the face, scalp, digits, mucosa, or skin that is scarred or previously treated with radiation.
• 3. History of treated nBCC lesion recurrence or basal cell nevus syndrome.
• 4. Immunocompromised, based on medical condition (e.g., human immunodeficiency virus), medication use, or other factors.
• 5. Active malignancy, excluding non-metastatic prostate cancer, other cutaneous basal or squamous cell carcinomas, and carcinoma of the cervix.
• 6. Used systemic chemotherapeutic agents within the 12 months prior to Visit 2/Baseline.
• 7. Clinical laboratory results at Visit 1/Screening within the following ranges: (a) granulocytes \< 2,000/mm3, (b) platelets \<50,000/mm3, (c) serum creatinine greater than 2 times the upper limit of normal (ULN), (d) aspartate aminotransferase, alkaline aminotransferase, lactate dehydrogenase, or alkaline phosphatase greater than 3 times the ULN.
• 8. History of sensitivity to any of the ingredients in the test articles .
• 12. Used topical immunomodulators within 2 cm of the Target Lesion within the 4 weeks prior to Visit 2/Baseline or after the confirmatory biopsy.
• 9. Used the following topical agents within 2 cm of the Target Lesion within the 4 weeks prior to Visit 2/Baseline or after the confirmatory biopsy: aminolevulinic acid, 5-fluorouracil, diclofenac, ingenol mebutate, tirbanibulin, or imiquimod.
• 10. Has been treated with liquid nitrogen, surgical excision or curettage within 2 cm of the Target Lesion within 4 weeks prior to Visit 2/Baseline or after the confirmatory biopsy.
• 11. Currently enrolled in an investigational drug, biologic, or device study. 12. Used an investigational drug, investigational biologic, or investigational device treatment within 30 days prior to enrollment into the study.
• 13. Unlikely to comply with the requirements of the study protocol (e.g., due to alcoholism, drug dependency, mental incapacity)